CRLBF
Price
$1.36
Change
+$0.04 (+3.03%)
Updated
Jan 14 closing price
Capitalization
486.4M
62 days until earnings call
Intraday BUY SELL Signals
DBCCF
Price
$0.08
Change
-$0.00 (-0.00%)
Updated
Jan 14 closing price
Capitalization
41.54M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRLBF vs DBCCF

Header iconCRLBF vs DBCCF Comparison
Open Charts CRLBF vs DBCCFBanner chart's image
Cresco Labs
Price$1.36
Change+$0.04 (+3.03%)
Volume$361.82K
Capitalization486.4M
Decibel Cannabis
Price$0.08
Change-$0.00 (-0.00%)
Volume$2.96K
Capitalization41.54M
CRLBF vs DBCCF Comparison Chart in %
CRLBF
Daily Signal:
Gain/Loss:
DBCCF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRLBF vs. DBCCF commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRLBF is a Hold and DBCCF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (CRLBF: $1.36 vs. DBCCF: $0.08)
Brand notoriety: CRLBF and DBCCF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRLBF: 24% vs. DBCCF: 2%
Market capitalization -- CRLBF: $483.9M vs. DBCCF: $41.54M
CRLBF [@Pharmaceuticals: Generic] is valued at $483.9M. DBCCF’s [@Pharmaceuticals: Generic] market capitalization is $41.54M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRLBF’s FA Score shows that 0 FA rating(s) are green whileDBCCF’s FA Score has 1 green FA rating(s).

  • CRLBF’s FA Score: 0 green, 5 red.
  • DBCCF’s FA Score: 1 green, 4 red.
According to our system of comparison, DBCCF is a better buy in the long-term than CRLBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRLBF’s TA Score shows that 6 TA indicator(s) are bullish while DBCCF’s TA Score has 4 bullish TA indicator(s).

  • CRLBF’s TA Score: 6 bullish, 4 bearish.
  • DBCCF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRLBF is a better buy in the short-term than DBCCF.

Price Growth

CRLBF (@Pharmaceuticals: Generic) experienced а +13.33% price change this week, while DBCCF (@Pharmaceuticals: Generic) price change was +2.82% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.08%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was +19.08%.

Reported Earning Dates

CRLBF is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRLBF($486M) has a higher market cap than DBCCF($41.5M). CRLBF YTD gains are higher at: 10.569 vs. DBCCF (-3.144). CRLBF has higher annual earnings (EBITDA): 112M vs. DBCCF (20.7M). CRLBF has more cash in the bank: 45.4M vs. DBCCF (6.08M). DBCCF has less debt than CRLBF: DBCCF (45.8M) vs CRLBF (581M). CRLBF has higher revenues than DBCCF: CRLBF (670M) vs DBCCF (109M).
CRLBFDBCCFCRLBF / DBCCF
Capitalization486M41.5M1,171%
EBITDA112M20.7M541%
Gain YTD10.569-3.144-336%
P/E RatioN/A3.52-
Revenue670M109M615%
Total Cash45.4M6.08M747%
Total Debt581M45.8M1,269%
FUNDAMENTALS RATINGS
CRLBF vs DBCCF: Fundamental Ratings
CRLBF
DBCCF
OUTLOOK RATING
1..100
2156
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
49
Fair valued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
9542
PRICE GROWTH RATING
1..100
4058
P/E GROWTH RATING
1..100
10015
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DBCCF's Valuation (49) in the null industry is in the same range as CRLBF (81). This means that DBCCF’s stock grew similarly to CRLBF’s over the last 12 months.

DBCCF's Profit vs Risk Rating (89) in the null industry is in the same range as CRLBF (100). This means that DBCCF’s stock grew similarly to CRLBF’s over the last 12 months.

DBCCF's SMR Rating (42) in the null industry is somewhat better than the same rating for CRLBF (95). This means that DBCCF’s stock grew somewhat faster than CRLBF’s over the last 12 months.

CRLBF's Price Growth Rating (40) in the null industry is in the same range as DBCCF (58). This means that CRLBF’s stock grew similarly to DBCCF’s over the last 12 months.

DBCCF's P/E Growth Rating (15) in the null industry is significantly better than the same rating for CRLBF (100). This means that DBCCF’s stock grew significantly faster than CRLBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRLBFDBCCF
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRLBF
Daily Signal:
Gain/Loss:
DBCCF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WMMCX11.400.12
+1.06%
TETON Westwood Mighty Mites C
BKDEX11.110.02
+0.18%
BlackRock Defensive Advantage EM K
RGGRX20.94-0.07
-0.33%
Victory RS Global R6
TICRX23.59-0.14
-0.59%
Nuveen Large Cap Responsible Eq A
CCWRX9.02-0.13
-1.42%
Columbia Select Large Cap Growth Inst3

CRLBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRLBF has been closely correlated with TSNDF. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRLBF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRLBF
1D Price
Change %
CRLBF100%
+3.03%
TSNDF - CRLBF
76%
Closely correlated
+3.05%
CURLF - CRLBF
76%
Closely correlated
+4.56%
TCNNF - CRLBF
75%
Closely correlated
+2.18%
JUSHF - CRLBF
74%
Closely correlated
+2.50%
GTBIF - CRLBF
72%
Closely correlated
-0.48%
More